HIV11: Infants Who Start Antiretrovirals Early Keep HIV Suppressed Despite Treatment Interruption

Babies who started taking lopinavir-based antiretroviral therapy (ART) soon after they were diagnosed with HIV experienced good virological response that was sustained through 6 years, even after they stopped treatment, according to long-term data from the CHER study presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.alt

HIV11: Dolutegravir Remains Effective for Treatment-experienced People with Multidrug-resistant HIV

The investigational HIV integrase inhibitor dolutegravir, which has shown comparable or superior efficacy to widely used drugs in clinical trials to date, works well for people with highly resistant HIV, including virus with mutations conferring resistance to other drugs in its class, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.alt

Pegylated Interferon May Maintain HIV Suppression and Reduce Viral DNA Integration

Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.alt

ICAAC 2012: Cobicistat-boosted Elvitegravir Does Not Interact with Methadone

The new HIV integrase inhibitor elvitegravir, boosted with cobicistat, does not cause clinically important changes in levels of methadone or buprenorphine used to manage opiate addiction, researchers reported at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco.alt

Immune Activation Raised HIV Risk in CAPRISA Trial, but Some Develop Protective Antibodies

Women in the CAPRISA 004 vaginal gel trial who showed evidence of prior immune activation had an increased likelihood of becoming infected with HIV, researchers recently reported. Another CAPRISA analysis found that 2 women exhibitedbroadly cross-neutralizing antibodies targeting a newly emergent antigen on HIV's envelope -- a discovery that could advance vaccine research.alt

Many People with HIV Skip Antiretroviral Therapy When They Drink Alcohol

About half of people who both take antiretroviral therapy (ART) and drink alcohol reported that they sometimes skip medication doses while drinking, according to a cohort study described in the October 12, 2012, advance online edition of the Journal of General Internal Medicine.alt

Antiretroviral Treatment Lowers Risk of Non-AIDS Illness in People Newly Diagnosed with HIV

Non-AIDS conditions are a significant cause of illness and death for people recently diagnosed with HIV, but starting antiretroviral therapy (ART) can reduce the likelihood of non-AIDS events including psychiatric and kidney problems, according to study findings published in the September 26, 2012, advance online edition of AIDS.alt